Vaccination Recommendations in Patients With Atopic Dermatitis Treated With JAK Inhibitors

Atopic dermatitis therapy has undergone a revolutionary change with the introduction of Janus kinase (JAK) inhibitors. Despite their general safety profile, these immunomodulatory drugs require special precautions with respect to infection risk and vaccine administration. This document aims to provide dermatologists and other healthcare practitioners with comprehensive practical vaccination recommendations for adults and adolescent patients with atopic dermatitis who are receiving or are about to receive treatment with JAK inhibitors. While inactivated vaccines are safe and recommended during JAK treatment, live attenuated vaccines are contraindicated unless treatment is temporarily discontinued according to clinical guidelines. It is crucial to follow vaccination guidelines established by official agencies and tailor them to individual patient needs. Careful consideration and follow-up are essential to ensure patient safety and optimal therapeutic outcomes.